The Path to Early Diagnosis and Early Treatment of Alzheimer’s Disease with a Disease-Modifying Approach

REGISTER NOW!
Already Registered?
SIGN IN

WEBCAST DATE

WEDNESDAY, OCTOBER 25, 2017

12:00 PM Eastern    11:00 AM Central    10:00 AM Mountain    9:00 AM Pacific

Faculty

Alireza Atri, MD, PhD
Ray Dolby Endowed Chair in Brain Health Research
Director, Research and Education,
Ray Dolby Brain Health Center
Senior Scientist, CPMC Research Institute
California Pacific Medical Center
San Francisco, CA
Visiting Scientist, Center for Brain/Mind Medicine,
Department of Neurology, Brigham & Women's Hospital,
Harvard Medical School, Boston, MA

PROGRAM AGENDA

I. Alzheimer’s disease (AD): an overview
  a. Disease pathophysiology (3D video)
  b. Biomarkers’ trajectories in the progression of AD
II. Importance of an early and accurate diagnosis of AD
  a. Work-up for AD diagnosis
    i. Tests and interpretation
    ii. Differentiation of mild cognitive impairment from aging, depression, or sleep disturbances
    iii. Updates in the Guidelines for Diagnostic Criteria (2011)
  b. Biomarkers for AD (MRI, FDG PET, Amyloid PET, CSF tau/Aβ42) and use in clinical practice
III. Treatment of early stages of AD in primary care
  a. Overview of current standard of care
  b. Emerging disease-modifying agents in development for early AD
    • Anti-amyloid agents, BACE1 inhibitors and other investigational agents (3D video)
    i. Clinical data update: solanezumab, aducanumab, crenezumab, BACE1 inhibitors, other investigational agents
    ii. Prevention trials update
    iii. Registries and clinical trials
IV. Case Studies
V. Alzheimer’s Association resources
VI. Conclusions/Questions/Adjournment

EDUCATIONAL OBJECTIVES

After completing the CME activity, learners should be better able to:

• Recognize the importance of an early differential diagnosis of Alzheimer’s disease to allow for early disease management or referral
• Describe current understanding of AD pathophysiology and review the use of cognitive and neuroimaging tests as part of a comprehensive evaluation for the early diagnosis of mild Alzheimer’s disease
• Discuss current and emerging therapeutic targets, and new data on investigational agents for treatment of mild AD with a disease-modifying approach to delay or slow AD progression
 

TARGET AUDIENCE

This activity is designed to meet the educational needs of neurologists, psychiatrists, internal medicine and family practitioners, and other HCPs (MDs, DOs, NPs, PAs, clinical nurse specialists, etc.) who are involved in the assessment and care of patients with cognitive impairment.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 Credit(s)^TM.

Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:

This program would be beneficial for nurses involved in the management of patients treated with AD.

1.0 ANCC Contact Hour(s)

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. 

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

AAPA ACCREDITATION

This program is not yet approved for credit by the AAPA. Conference organizers have requested 1.0 hours of AAPA Category 1 CME Credit from the Physician Assistant Review Panel. Total number of approved credits yet to be determined.

AOA CREDIT

The American Osteopathic Association (AOA) Council on Continuing Medical Education has APPROVED this activity for 1 AOA Category 2-A credits.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event Staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.) Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

Copyright © 2017 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.